Nkarta, Inc. Common Stock (NKTX) Stock
Key stats
- Market cap
- $106.00M
- Price / Earnings ratio
- -0.8x
- EPS (TTM)
- -$1.73
- Volume
- Loading
- 52-week high
- $3.72
- 52-week low
- $1.13
Source: third-party data provider, as of November 13, 2026
Compare with NKTX
Recent news

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
NKTX

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
NKTX

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
NKTX

3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket
3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket
NKTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 36.67
- MACD 12/26/9
- -0.20
- EMA 9 of MACD
- -0.21
- MACD histogram
- 0.01
- SMA 50
- $2.26
- Price below SMA 50
- EMA 50
- $2.06
- Price below EMA 50
- SMA 200
- $2.51
- Price below SMA 200
- EMA 200
- $2.33
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
NKTX

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
NKTX

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
NKTX

3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket
3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket
NKTX

3 Sleeper Stocks With Serious Potential to Make You a Millionaire
3 Sleeper Stocks With Serious Potential to Make You a Millionaire
NKTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Nkarta, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul J. Hastings | CEO & Director | 1960 |
| Dr. Nadir Mahmood Ph.D. | President and Principal Accounting & Financial Officer | 1980 |
| Dr. Shawn Rose M.D., Ph.D. | Chief Medical Officer and Head of Research & Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 36.67
- MACD 12/26/9
- -0.20
- EMA 9 of MACD
- -0.21
- MACD histogram
- 0.01
- SMA 50
- $2.26
- Price below SMA 50
- EMA 50
- $2.06
- Price below EMA 50
- SMA 200
- $2.51
- Price below SMA 200
- EMA 200
- $2.33
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $11.00
- High
- $12.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.0 | +15.8 | ||||||||||
| 2022 | -33.9 | -11.8 | +31.4 | +61.2 | -23.1 | -9.5 | +2.5 | +15.5 | -9.6 | -4.1 | -33.2 | -28.4 |
| 2023 | -11.6 | -24.6 | -17.8 | +31.3 | -10.6 | -52.3 | +5.0 | -23.9 | -21.5 | +55.0 | +38.2 | +142.6 |
| 2024 | +41.9 | +13.9 | -15.8 | -38.3 | -9.3 | -13.5 | +9.9 | -17.2 | -12.2 | -26.8 | -10.0 | -17.8 |
| 2025 | -6.4 | -19.4 | +13.6 | +14.6 | -15.1 | -4.0 | +26.9 | +0.0 | -1.4 | -0.9 | -8.7 | +2.2 |
| 2026 | +18.7 | +25.0 | -21.9 | +26.5 | +10.9 | -9.9 | -26.7 | +26.0 | -3.0 | -39.1 | -2.6 |



